Dextromethorphan and guaifenesin use must be monitored very carefully in clients with "very poor metabolizer" CYP2D6 enzyme concentrations and patients who will be sedated. This combination medication provides a significant median harmful dose (TD50) to median successful dose (ED50) ratio (or therapeutic index) in these individuals. mutation The result of https://chemicalglobe.com/shop/dxm/buy-dxm-powder-online/